Savara Inc. SVRA

Updated: 17 Jun 2026

NASDAQ | Biotech | Rare respiratory diseases

No signal published yet

We already track Savara and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Savara free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Rare respiratory diseases
We're already tracking Savara Inc. — here are the latest events we've registered

Recent News

  • In June 2026, Savara announced that CFO Dave Lowrance will step down for health reasons on July 15, with COO Robert Lutz assuming the additional role. Shareholders approved doubling the authorized common shares to 600 million, and the company is targeting a PDUFA action date of November 22, 2026, for its lead candidate MOLBREEVI.

What Firelda Watch includes for Savara Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Savara Inc. will be delivered in the same format.

Want to follow Savara Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Savara free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Savara Inc. SVRA
Savara — follow and we'll monitor it
Follow Savara free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.